Nicole C. Ammerman, PhD, ScM

Staff

Titles:

Research Associate, Medicine, Infectious Disease, TB Center

Email:

nicole.ammerman@jhu.edu

Phone:

410-292-2957

SciVal:

SciVal Link

The fundamental basis of my work is to use science to advance the global control of tuberculosis and limit the suffering of people with tuberculosis and nontuberculous mycobacterial diseases. Specifically, my research efforts are focused on improving the treatment of these diseases by using in vitro and in vivo experimental chemotherapy models to evaluate the antimycobacterial activity of compounds, drugs, and regimens; and to study drug, host, and pathogen factors that influence treatment outcome. My research is translational; the ultimate goal of all my work is to provide reliable preclinical data that can be used to inform drug and regimen development and clinical trial design. Current research projects include investigation of the treatment-shortening potential of clofazimine in regimens for drug-susceptible tuberculosis; evaluation of a long-acting injectable formulation of bedaquiline for tuberculosis preventive therapy; and development of nontuberculous mycobacteria infection models for treatment studies.

Categories

Events

«

June 2019

»
S
M
T
W
T
F
S
·
·
·
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
·
·
·
·
·
·

Projects

Modeling to improve TB decision-making in the...

We are part of a large consortium that is constructing epidemic and economic models of TB and HIV in collaboration with the U.S....

Read More

Statins as Adjunctive, Host-Directed Therapy...

The goal of this study is to investigate the potential utility of pravastatin as an adjunctive, host-directed therapy for...

Read More

Understanding the impact of combined TB and...

We are developing models to understand the overlap of TB and HIV in three epidemiologically distinct settings (Canada, India,...

Read More

Scale-up and implementation of TB diagnostics...

We are evaluating the implementation, cost-effectiveness, and potential epidemiological impact of scaling up Xpert across 19...

Read More